Will Pierre Fabre and Array Have Best-In-Class MEK/BRAF Inhibitor?
Executive Summary
Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.
You may also be interested in...
Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
UK NICE OKs Melanoma Combo Treatment From Array/Pierre Fabre
Array BioPharma/Pierre Fabre’s combination treatment for metastatic melanoma has received NICE's go-ahead for funding under the national health service in England and Wales.
Array BioPharma Recruits Pierre Fabre As European Partner
The ability of Pierre Fabre to compete in the near term against oncology heavyweights like Novartis and Roche was key to selecting the French company to commercialize and further develop Array BioPharma's MEK inhibitor binimetinib and BRAF inhibitor encorafenib in Europe and emerging markets.